-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers proposed supplementing with omega-3 polyunsaturated fatty acids (ω-3 PUFA) and low-dose aspirin (ASA) as a host-regulatory program to control chronic inflammatory diseases.
Recently, researchers have explored the clinical and immunological effects of oral omega-3 PUFA and ASA as an auxiliary periodontal debridement in the treatment of periodontitis in patients with type 2 diabetes.
The results have been published in J Periodontol.
A total of 75 patients (n=25/group) were included in the study, and they were randomly assigned to receive placebo and periodontal debridement (CG).
After periodontal debridement, they received omega-3 PUFA+ASA (3 g fish oil/d+100 mg ASA/d, 2 months) (experimental group [TG]1), or receive omega-3 PUFA+ASA (3 g fish oil/d+100 mg ASA/d, 2 months) before periodontal debridement ( TG2).
Periodontal parameters and GCF were collected at baseline (t0).
TG1 and CG(t1) were collected after periodontal debridement and ω-3 PUFA+ASA or placebo at 3 months, and TG2(t1) was at ω-3 PUFA+ASA( Before periodontal debridement), and 6 months after periodontal debridement (all groups) (t2).
GCF analyzes cytokine levels by multi-link ELISA.
The results showed that 10 patients (40%) in TG1 and 9 patients (36%) in TG2 reached the clinical endpoint of treatment (less than 4 sites with a probing depth ≥5mm), while only 4 patients in CG (16 %).
The moderate to severe periodontal deep pockets in the TG1 group all had clinical attachments increased.
The levels of IFN-γ and interleukin (IL)-8 in the two experimental groups decreased over time.
TG1 has a low level of IL-6.
The HbA1c level of TG1 decreased.
In summary, the results of this study show that adjuvant omega-3 and ASA after periodontal debridement have clinical and immunological significance for the treatment of periodontitis in type 2 diabetic patients.
Original source: Nidia C Castro Dos Santos, Naira MRB Andere, et al.
, Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial.
J Periodontol.
2020 Oct;91( 10):1318-1327.
doi: 10.
1002/JPER.
19-0613.
For more information, please click to read the original text to download the Metz Medical APP~
Recently, researchers have explored the clinical and immunological effects of oral omega-3 PUFA and ASA as an auxiliary periodontal debridement in the treatment of periodontitis in patients with type 2 diabetes.
The results have been published in J Periodontol.
A total of 75 patients (n=25/group) were included in the study, and they were randomly assigned to receive placebo and periodontal debridement (CG).
After periodontal debridement, they received omega-3 PUFA+ASA (3 g fish oil/d+100 mg ASA/d, 2 months) (experimental group [TG]1), or receive omega-3 PUFA+ASA (3 g fish oil/d+100 mg ASA/d, 2 months) before periodontal debridement ( TG2).
Periodontal parameters and GCF were collected at baseline (t0).
TG1 and CG(t1) were collected after periodontal debridement and ω-3 PUFA+ASA or placebo at 3 months, and TG2(t1) was at ω-3 PUFA+ASA( Before periodontal debridement), and 6 months after periodontal debridement (all groups) (t2).
GCF analyzes cytokine levels by multi-link ELISA.
The results showed that 10 patients (40%) in TG1 and 9 patients (36%) in TG2 reached the clinical endpoint of treatment (less than 4 sites with a probing depth ≥5mm), while only 4 patients in CG (16 %).
The moderate to severe periodontal deep pockets in the TG1 group all had clinical attachments increased.
The levels of IFN-γ and interleukin (IL)-8 in the two experimental groups decreased over time.
TG1 has a low level of IL-6.
The HbA1c level of TG1 decreased.
In summary, the results of this study show that adjuvant omega-3 and ASA after periodontal debridement have clinical and immunological significance for the treatment of periodontitis in type 2 diabetic patients.
Original source: Nidia C Castro Dos Santos, Naira MRB Andere, et al.
, Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial.
J Periodontol.
2020 Oct;91( 10):1318-1327.
doi: 10.
1002/JPER.
19-0613.
For more information, please click to read the original text to download the Metz Medical APP~
